Phase 1b open-label study of loncastuximab tesirine in combination with other anticancer agents in patients with relapsed/refractory B-cell Non-Hodgkin lymphoma (LOTIS-7)

Emily C Ayers; Julien Depaus; Fritz Offner; Marie Hu; Craig Okada; Andrzej Urban; Andrew Niewiarowski; Erica Rave; Mary Laughlin; Juan Pablo Alderuccio

$Phase 1b open-label study of loncastuximab tesirine in combination with other anticancer agents in patients with relapsed/refractory B-cell Non-Hodgkin lymphoma (LOTIS-7)$

Conference proceeding

Peer reviewed

Phase 1b open-label study of loncastuximab tesirine in combination with other anticancer agents in patients with relapsed/refractory B-cell Non-Hodgkin lymphoma (LOTIS-7)

Emily C Ayers, Julien Depaus, Fritz Offner, Marie Hu, Craig Okada, Andrzej Urban, Andrew Niewiarowski, Erica Rave, Mary Laughlin and Juan Pablo Alderuccio

2024

Appears in Miller School of Medicine - Latest Publications

Abstract

ABCL

glofitamab

loncastuximab tesirine

Medicine and Health Sciences

mosunetuzumab

non-Hodgkin lymphoma

phase 1

trial-in-progress

Metrics

1 Record Views

Details

Title: Phase 1b open-label study of loncastuximab tesirine in combination with other anticancer agents in patients with relapsed/refractory B-cell Non-Hodgkin lymphoma (LOTIS-7)
Creators: Emily C Ayers
Julien Depaus
Fritz Offner
Marie Hu
Craig Okada
Andrzej Urban
Andrew Niewiarowski
Erica Rave
Mary Laughlin
Juan Pablo Alderuccio
Academic Unit: Miller School of Medicine; UMMG Dept of Medicine - Hematology/Oncology
Language: English
Resource Type: Conference proceeding
Record Identifier: 991032860809902976